Encouragingly, improved cognition was recently observed in both patients with schizophrenia and dementia in early clinical trials involving the administration of the DAO inhibitor sodium benzoate (Lane et al., 2013; Lin et al., 2014). The gene discussed is DAO; the disease is dementia.